socalTECH

FEBRUARY 22, 2012

Thousand Oaks-based Ceres , the developer of specialized seeds for the biofuels market, has priced its IPO, saying that it will offer up 5,000,000 shares of its common stock at $13.00 per share IPO range, after seeing a delay of a week in the expected pricing by the firm.

Pricing 150

Pricing Thousand Oaks Startup Design 150

socalTECH

FEBRUARY 8, 2012

Thousand Oaks-based Ceres , the developer of seeds for producing renewable bioenergy feedstocks, has cut its estimated IPO pricing range, ahead of its anticipated IPO this week. In an updated S-1, Ceres now estimates that it will price at between $16.00 Ceres had earlier estimated pricing at between $21.00

Pricing 133

Pricing Thousand Oaks Develop Development 133

socalTECH

JANUARY 25, 2012

Thousand Oaks-based Ceres , the developer of seeds to supply the bioenergy and biofuels feedstock business, has set its initial pricing range for its IPO, according to a filing from the company this morning. Ceres said it now expects its IPO to price at between $21.00 and $23.00

Pricing 145

Pricing Thousand Oaks Design Capital 145

socalTECH

JANUARY 30, 2012

Thousand Oaks-based Ceres , which develops specialized seeds for the biofuels industry, is planning to hit the market on February 9th, according to the NASDAQ IPO calendar. Ceres recently estimated its IPO pricing at between $21.00 If successful, the offering will raise $132.25M for the company. and $23.00

Thousand Oaks 153

Thousand Oaks Marketing Southern California Pricing 153

socalTECH

FEBRUARY 23, 2012

Thousand Oaks-based Ceres , the biotechnology firm developing specialized seed stocks for the biofuels industry, rose in its IPO on Wednesday, closing at $14.80 The firm priced its IPO on Tuesday evening at $13.00 per share, pricing lower than expected after a delay in its IPO.

Thousand Oaks 145

Thousand Oaks Southern California Pricing Activity 145

Xconomy

JUNE 10, 2016

The results give the company confidence it can expand its tests to screen for early cancer in high-risk people who are otherwise healthy. As the conference wrapped up, a Morgan Stanley analyst noted that Pfizer the previous week had raised its drug prices nine percent, continuing a regular pattern of price increases.

Incubator 67

Incubator Thousand Oaks Screening Pricing 67

Xconomy

AUGUST 26, 2016

Mylan bumped up the price of the EpiPen 400 percent, presidential nominee Hillary Clinton responded with a tirade against drug price hikes, and—much like when Clinton railed against drug pricing last year—biotech indexes promptly plummeted more than 3 percent. It was the tweet heard around the biotech world, again.

Pricing 40

Pricing Thousand Oaks Startup Research 40